MedTrace Logo

Study to Evaluate SYN115 in Parkinson's Disease

NCT00605553 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-08-08

No results posted yet for this study

Summary

This is an exploratory study to evaluate if SYN115 has an effect on Parkinson's disease as measured by clinical symptoms and brain images using magnetic resonance imaging (MRI) when a function test is administered.

Conditions

Interventions

DRUG

Placebo

Placebo oral capsules Placebo for 7 days

DRUG

Tozadenant

20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID

Sponsors & Collaborators

  • Biotie Therapies Inc.

    lead INDUSTRY

Principal Investigators

  • Steve Bandak, MB BS MRCP · Synosia Therapeutics

  • Ann Neale, RN · Synosia Therapeutics

  • Uwe Meya, MD · Synosia Therapeutics

  • Kevin J Black, MD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00605553 on ClinicalTrials.gov